Novavax (NVAX) Covid-19 Vaccine Induces Immune Response in First Human Study, Company Says - DJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Novavax (NVAX) PT Raised to $257 at B.Riley/FBR
August 5, 2020 6:57 AM EDTB.Riley/FBR analyst Chad L. Mabry raised the price target on Novavax (NASDAQ: NVAX) to $257.00 (from $184.00) while maintaining a Buy rating.
... MoreNovavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate
August 5, 2020 6:24 AM EDTNovavax, Inc. (NASDAQ: NVAX) today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID19 vaccine with and without MatrixM adjuvant in healthy adults 18-59 years of age. NVXCoV2373, the Companys recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. The data have been submitted for peer-review to a scientific journal and to an online preprint server at medRxiv.org.
NVX-CoV2373 was well-tolerated and had a reassuring safety profile.
Overall,... More
Novavax (NVAX) Erases Post-Market Decline, Now Up 13%
August 4, 2020 5:46 PM EDTNovavax (NASDAQ: NVAX) Erases Post-Market Decline, Now Up 13%
